Recombinant TNFSF11 (Denosumab Biosimilar) anticorps

N° du produit ABIN7200656

Détail du produit anti-TNFSF11 (Denosumab Biosimilar) anticorps

Antigène: TNFSF11 (Denosumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TNFSF11 (Denosumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Fonction: Denosumab Biosimilar, Human RANKL Monoclonal Antibody

Specificité: The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.

Attributs du produit: Recombinant Humanized IgG2 Monoclonal Antibody.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The monoclonal antibody denosumab biosimilar was produced in the denosumab biosimilar CHO stable cell line.

Isotype: IgG2 kappa

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur TNFSF11 (Denosumab Biosimilar)

Antigène: TNFSF11 (Denosumab Biosimilar)

Abstract: TNFSF11 (Denosumab Biosimilar) Produits

Synonymes: anticorps CD254, anticorps ODF, anticorps OPGL, anticorps OPTB2, anticorps RANKL, anticorps TRANCE, anticorps hRANKL2, anticorps sOdf, anticorps TNF superfamily member 11, anticorps TNFSF11

Classe de substances: Biosimilar

Sujet: Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.